Redeye comments on Tessin’s Q1 results, which showed solid growth despite a significant cost reducti...
Redeye states its view of Xavi Solutions’ Q1 2023 report, released earlier today.
Weaker EBIT partly due to lower than expected Öyfjellet contribution Project portfolio of ~24.
ITAB’s Q1 report was weak, with key retail clients remaining cautious and the company investing heav...
Redeye leaves its comments on Acarix following its Q1 2023 report, which did not contain any major s...
Sales and earnings lower than expected Earnings hit by underperforming contracts in Greenland Strong...
Redeye states that Truecaller delivered revenues below estimates, but that adjusted EBIDTA beat cons...
Segment EBIT SEK 12m (ABGSCe 10m), but OH costs -26m Sees strong outlook for both regions Net cash p...
Redeye sees a strong Q1 report from Speqta with accelerating net customer intake, strengthening our ...
Redeye updates on W5 Solutions after its Q1-results which saw somewhat higher revenue and EBITDA tha...
Redeye comments on Spago’s Q1 2023 report, and we judge the coming 2-3 months will provide some inte...
Redeye saw a Q1 report that was slightly weaker than expected but not a material deviation.
Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company nee...
Redeye provides its comment on Ultimovacs’ Q1 2023 report, which featured no surprises.
Redeye updates its estimates following Freemelt’s Q1 report.
A solid 9% organic growth and lower opex in Q1 We raise EBITDA by SEK 2m and SEK 4m on '23e-'24e Sha...
Tillväxtresan fortsätter och Devyser växer organiskt med 22% i Q1.
Good cost control and FCF despite no orders Sales organisation restructured to increase future sales...
